ABSTRACT
In a series of 30 SARS-COV-2 infected patients whom clinically proven as severe pulmonary infection form. These were found with male/female ratio of 1:1. The age range of below 50 years old account for 60% and those of above 50 years old constitute the remaining 40%. They were the residents of Merjan Teaching Hospital/ Babylon Province/Iraq, to the period of March to April 2021 and primary screen by PCR for Sars-cov-2 RNA genes, in public health central laboratory found to be positive. The over- all laboratory investigation were; D -dimer, Ferritin, LDH, acute phase reactant C, and IL6. LDH was tempted to probe the immune mediated pulmonary tissue injury (367.48 U/L.), ferritin response may indicate hemolytic and acute phase reactant expressed as hyper-inflammation (331.1 ng/L.). |The D-dimer shed a light on the fibrino-lytic responses (6049 ng/L.) post to the immune-thrombotic overreactions, where IL6 levels give a clue to the state of hyper-cytokinemia (171.92 pg/L.). The overall immune status of these patients was as; Hyper-inflammatory and immune overreaction. The inflammatory and immune herd plots were of skewed distribution types.
ABSTRACT
BACKGROUND: The clinical course of severe COVID-19 in cystic fibrosis (CF) is incompletely understood. We describe the use of alpha-1 antitrypsin (AAT) as a salvage therapy in a critically unwell patient with CF (PWCF) who developed COVID-19 while awaiting lung transplantation. METHODS: IV AAT was administered at 120 mg/kg/week for 4 consecutive weeks. Levels of interleukin (IL)-1ß, IL-6, IL-8, and soluble TNF receptor 1 (sTNFR1) were assessed at regular intervals in plasma, with IL-1ß, IL-6, IL-8 and neutrophil elastase (NE) activity measured in airway secretions. Levels were compared to baseline and historic severe exacerbation measurements. RESULTS: Systemic and airway inflammatory markers were increased compared to both prior exacerbation and baseline levels, in particular IL-6, IL-1ß and NE activity. Following each AAT dose, rapid decreases in each inflammatory parameter were observed. These were matched by marked clinical and radiographic improvement. CONCLUSIONS: The results support further investigation of AAT as a COVID-19 therapeutic, and re-exploration of its use in CF.